|
Institute for Myeloma and Bone Cancer Research
From their web site:
The "Cure Myeloma Project" enlists a full time research staff at The Institute for Myeloma and Bone Cancer Research. ... One of the hallmarks on the road to a cure is that these research efforts have extended the lifespan of p |
258 |
|
|
Dr. James R. Berenson
We're told, "Dr. Berenson is a noted myeloma and bone cancer specialist whose diligent scientific efforts have lead to several breakthroughs in the field hematologic cancers. As a physician-scientist, Dr. Berenson has a thriving oncology practice an |
173 |
|
|
Mayo Clinic advises on multiple myeloma Rx
ROCHESTER, Minn., Aug. 11 (UPI) -- U.S. Mayo Clinic researchers Friday issued their advice on the best choice of a drug class called bisphosphonates for multiple myeloma. The drugs are used to treat or prevent bone disease in patients with the condit |
666 |
|
|
Two guys named Dave on death and life with cancer
(Villagesoup.com, July 21, 2006) _ David Demere was about as sick as you can be and still function as he boarded a plane for Florida last January. He had cancer in 95 percent of his bone marrow, and both his vertebrae and ribs were traced with a spid |
641 |
|
|
Acceleron Initiates Phase I Clinical Trail of ACE-0011, a Novel Treatment for Bone Loss
(Press Release, June 21, 2006) _ Acceleron Pharma, Inc., a biopharmaceutical company involved in the development of regenerative therapeutics, announced that it has initiated a Phase 1 clinical trial of ACE-011, a novel treatment for bone loss |
314 |
|
|
Millennium Releases Cancer Study Results
(Associated Press, June 21, 2006) _ Millennium Pharmaceuticals Inc. said Wednesday a study showed that its multiple myeloma treatment Velcade was effective in combination with two other drugs as a first-line treatment in elderly patients. The stu |
351 |
|
|
Data from Phase I Clinical Trial of Quadramet in Patients with Relapsed Multiple Myeloma
Cytogen Corporation announced interim results from a phase I clinical trial of QUADRAMET® (samarium Sm-153 lexidronam injection) in combination with bortezomib (Velcade®, Millennium Pharmaceuticals, Inc.) in patients whose multiple myeloma has |
333 |
|
|
Data Demonstrate Potential of Bortezomib for Injection Across Solid and Hematological Cancers
(Doctor's Guide - ATLANTA, GA -- June 16, 2006) _ Millennium Pharmaceuticals, Inc. today announced results from additional studies of Velcade (bortezomib) in a variety of cancers, including multiple myeloma, non-Hodgkin's lymphoma and non-small cell |
318 |
|
|
Addition of Thalidomide to Standard Therapy Improves Overall Survival in Newly Diagnosed Multiple Myeloma
(Doctor's Guide-OULDER, CO -- June 15, 2006) _Pharmion Corporation reported that data presented at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Atlanta, GA (June 2-6, 2006) demonstrates that the addition of thalidomi |
364 |
|
|
Celgene Says Treatment With R-MP In Multiple Myeloma, Halts Disease Progression
(RealTimeTraders.com, June 5, 2006) _ Monday, Celgene Corporation, an integrated global pharmaceutical company, said data from a study with combination therapy lenalidomide, melphalan and prednisone or R-MP in elderly newly diagnosed multiple myelom |
336 |
|
|
40% of Multiple Myeloma Patients Respond to Single Agent Bortezomib
(DGDispatch, June 5, 2006) - In a trial of bortezomib (Velcade) monotherapy, 10% of multiple myeloma patients achieved complete remission and another 30% achieved objective response, researchers reported here at the American Society of Clinical Onco |
361 |
|
|
No Survival Difference Seen In Multiple Myeloma Patients With High-Dose Compared With Low-Dose Thalidomide
(DGDispatch- June 5, 2006) _ Patients with refractory-relapsed multiple myeloma may have equally successful treatment outcomes regardless of whether they receive thalidomide at 100 mg/day or 400 mg/day, researchers reported here at the American Soci |
395 |
|
|
Revlimid boosts survival in multiple myeloma: study
(Reuters -June 5, 2006) - Celgene Inc.'s cancer drug Revlimid improves the rate of survival in previously treated patients with the blood cancer multiple myeloma by at least a year compared with those taking standard treatment, according to data rele |
376 |
|
|
Celgene drug boosts multiple myeloma survival-study
(Reuters, June 4, 2006) - Celgene Inc. said on Sunday its cancer drug Thalomid improved survival by a significant amount in elderly patients with multiple myeloma, a form of blood cancer. |
331 |
|
|
Longtime television host Louis Rukeyser dead at age 73
(Hartford-AP, May 3, 2006 6:15 AM) _ For more than three decades, Louis Rukeyser delivered pun-filled, commonsense commentary on complicated business and economic news as a best-selling author, columnist, lecturer and television host. Rukeyser, 73, d |
411 |
|
|
Tribute to tragic dad as pals say cheers with special brew
(Evening Times Apr. 20, 2006) _ Friends and family of a beer enthusiast who died of cancer are helping save lives - with a special brew made in his memory. |
312 |
|
|
Running in honor of a man and a cause
(Wellesley Townsman, Apr. 13, 2006) _ As he starts the Boston Marathon next Monday, Paul Criswell’s attention will be on the task of finishing, but his heart will be with his critically ill father-in-law. |
288 |
|
|
Scientists Discover New Genetic Subtypes Of Common Blood Cancer
(Science Daily, Apr. 11, 2006) _ Scientists at Dana-Farber Cancer Institute and collaborators have identified four distinct genetic subtypes of multiple myeloma, a deadly blood cancer, that have different prognoses and might be treated most effective |
544 |
|
|
Merck Sued Over Fosamax Health Risks
(LA TIMES, April 11, 2006) _ Merck & Co., which faces more than 9,000 lawsuits over its Vioxx painkiller, misrepresented the safety of its osteoporosis drug Fosamax by withholding warnings that it could kill jawbone tissue, according to a lawsuit fil |
292 |
|
|
Experts Debate Thalidomide's Promise Against Myeloma
FRIDAY, March 10 (HealthDay News) -- The once-banned drug thalidomide appears to improve treatment for patients battling the blood cancer multiple myeloma, a new study shows, but the jury is still out on its impact on their long-term survival. |
337 |
|
|
Confusing news stories about the efficacy of thalidomide
March 14, 2006 (International Myeloma Foundation) - Thalidomide has been used since 1997 in the treatment of myeloma. Remarkable efficacy has been observed both alone and in combination with dexamethasone and other drugs. Strangely, only recently hav |
394 |
|
|
Study casts doubt on value of thalidomide against bone-marrow cancer
(Associated Press) _ Thalidomide, a drug that caused ghastly birth defects a generation ago but has been resurrected in recent years as a promising cancer treatment, failed in a study to prolong the lives of patients with multiple myeloma. |
393 |
|
|
Study: Thalidomide boosts short-term survival in multiple myeloma patients
(Associated Press) _ On the heels of disappointing results for thalidomide as a treatment for bone marrow cancer, a smaller study suggests the drug may prolong survival of elderly patients, but at a price. |
464 |
Cancer Links 